# Effects of FABP5 Expression on Clinicopathological and Survival Characteristics in Digestive System Malignancies: A Systematic Review and Meta‐Analysis

**Authors:** Miaoqing Li, Xiaoxia Wang, Jia Guo, Junchen Qu, Yu Cao, Qingkun Song, Jun Lu

PMC · DOI: 10.1002/cam4.70794 · Cancer Medicine · 2025-04-03

## TL;DR

This study finds that high FABP5 levels are linked to worse outcomes in digestive cancers, suggesting it could be a useful biomarker.

## Contribution

The study provides a meta-analysis and mechanistic insights into FABP5's role in digestive system malignancies.

## Key findings

- FABP5 overexpression is associated with poorer survival and advanced tumor features in digestive cancers.
- FABP5 promotes cancer cell growth and spread in liver and stomach cancer cell lines.
- FABP5 may drive tumor progression through PPARβ/δ and other related pathways.

## Abstract

Digestive system malignancies are a major global health burden, and the role of fatty acid binding protein 5 (FABP5) in these tumors remains controversial.

This meta‐analysis aimed to evaluate the correlation between FABP5 expression and clinicopathological features, as well as survival outcomes in digestive system malignancies.

Data from 11 studies (1207 patients) retrieved from PubMed, Embase, Cochrane Library, CNKI, and WanFang were analyzed.

FABP5 overexpression was associated with poorer overall survival (OS), larger tumor size, advanced UICC stage, and increased risk of vascular invasion and lymph node metastasis. Notably, FABP5 overexpression is particularly associated with poorer OS in the subgroup of digestive tract malignancies and larger tumor sizes in the subgroup of Chinese patients.

Cellular experiments demonstrated that FABP5 overexpression enhances proliferation, migration, and invasion in hepatocellular carcinoma (Huh7) and gastric cancer (HGC‐27) cell lines, while FABP5 knockdown reduces these effects. Mechanistically, FABP5 may drive tumor progression through PPARβ/δ signaling, epithelial‐mesenchymal transition induction, angiogenesis regulation, and potential effects on fatty acid metabolism and hypoxia‐related pathways.

FABP5 overexpression correlates with adverse clinicopathological features and prognosis in digestive system malignancies, suggesting its potential as a biomarker for these tumors. Further research is warranted.

## Linked entities

- **Genes:** FABP5 (fatty acid binding protein 5) [NCBI Gene 2171]
- **Diseases:** hepatocellular carcinoma (MONDO:0007256), gastric cancer (MONDO:0001056)

## Full-text entities

- **Genes:** FABP5 (fatty acid binding protein 5) [NCBI Gene 2171] {aka E-FABP, EFABP, KFABP, PA-FABP, PAFABP}
- **Diseases:** hypoxia (MESH:D000860), gastric cancer (MESH:D013274), lymph node metastasis (MESH:D008207), Digestive System Malignancies (MESH:D004066), hepatocellular carcinoma (MESH:D006528), digestive tract malignancies (MESH:D004828), tumor (MESH:D009369)
- **Chemicals:** fatty acid (MESH:D005227)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HGC-27 — Homo sapiens (Human), Gastric carcinoma, Cancer cell line (CVCL_1279), Huh7 — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_0336)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11966564/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11966564/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC11966564/full.md

---
Source: https://tomesphere.com/paper/PMC11966564